NasdaqCM:AXGNMedical Equipment
Axogen (AXGN) Is Up 10.3% After Raising 2026 Revenue Outlook Despite Wider Q1 Loss – Has The Bull Case Changed?
Axogen, Inc. reported first-quarter 2026 results showing sales of US$61.46 million versus US$48.56 million a year earlier, alongside a wider net loss of US$19.58 million and loss per share of US$0.38.
Despite the higher loss, Axogen raised its 2026 outlook, projecting at least 20% revenue growth to about US$270 million and a gross margin of 74% to 76%, reinforcing management’s confidence in the company’s nerve repair platform.
We’ll now examine how Axogen’s raised 2026 revenue and margin...